Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy

NCT00522457 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

19

Enrollment

INDUSTRY

Sponsor class

Stopped change in development plan, not due to safety concerns.

Conditions

Metastatic Breast Cancer
Advanced Breast Cancer

Interventions

DRUG: ertumaxomab

Sponsor

Neovii Biotech

Collaborators

[object Object]